RPG Life Sciences completes slump sale of APIs business to Raghava

0 min read | Published on 16 Sept 2026, 01:56 AM |Updated on 16 Sept 2026, 01:56 AM

Reviewed by

Suketu GScanX News Team

Add as a preferred
source on Google

Key Highlights

RPG Life Sciences completes slump sale of APIs and intermediates business
Buyer is Raghava Life Sciences Private Limited
Transaction executed via subsidiary RPG Active Pharma Limited
Transfer effective from September 16, 2026

*this image is generated using AI for illustrative purposes only.

RPG Life Sciences has completed the slump sale of its Active Pharmaceutical Ingredients (APIs) and intermediates business to Raghava Life Sciences Private Limited. The transfer is effective from September 16, 2026.

The transaction was executed through a Business Transfer Agreement (BTA) between Raghava Life Sciences and RPG Active Pharma Limited, a wholly owned subsidiary of RPG Life Sciences. The deal involves the acquisition of the APIs and intermediates businesses as a going concern.

Transaction Details

RPG Life Sciences disclosed the completion to the National Stock Exchange of India Limited and BSE Limited under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The company had previously informed the exchanges about the execution of the BTA on September 2, 2026.

Detail	Information
Buyer	Raghava Life Sciences Private Limited
Seller	RPG Active Pharma Limited
Business Unit	APIs and intermediates
Effective Date	September 16, 2026
Transaction Type	Slump sale (going concern)

Historical Stock Returns for RPG Life Sciences

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.75%	-0.10%	+3.24%	+43.01%	+13.80%	0.0%

How will RPG Life Sciences reallocate the capital from the API business sale to drive future growth in its core pharmaceutical segments?

What strategic advantages does Raghava Life Sciences gain by acquiring this API and intermediates unit as a going concern?

Will the slump sale impact RPG Life Sciences' current supply chain stability for its finished dosage forms in the short term?

RPG Life Sciences

View Company Insights

View All News

RPG Life Sciences eyes acquisitions to expand API portfolio in 12 months

0 min read | Published on 04 Sept 2026, 09:11 AM |Updated on 04 Sept 2026, 09:11 AM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Key Highlights

RPG Life Sciences plans more acquisitions to expand its API portfolio over the next 12 months
The strategy reflects an inorganic growth approach for the company's active pharmaceutical ingredients business
The development was reported by a newspaper

*this image is generated using AI for illustrative purposes only.

RPG Life Sciences is looking to make more acquisitions to expand its active pharmaceutical ingredients portfolio over the next 12 months, according to a newspaper report.

Acquisition strategy for API growth

The company's focus on inorganic expansion signals a deliberate push to strengthen its API business. By targeting acquisitions within a defined 12-month window, RPG Life Sciences aims to broaden the range of active pharmaceutical ingredients it offers, adding depth to its existing product base.

The API segment is a critical part of the pharmaceutical value chain, supplying the core chemical compounds used in finished drug formulations. Expanding this portfolio through acquisitions can allow a company to serve a wider set of therapeutic areas and customer requirements.

Historical Stock Returns for RPG Life Sciences